KRAS codon 12 and 13 mutations are widely accepted as a predictive biomarker of lack of response to anti-EGFR therapy in metastatic colorectal cancer[19-23], though a few exploratory studies suggest that codon 13 mutants may benefit from EGFR-targeted therapy[24,25]. Here, EGFR is linked to metastatic colorectal cancer.